Trial Summary
What is the purpose of this trial?Patients with brain hemorrhage resulting from a ruptured aneurysm (SAH) are at risk of developing a condition called vasospasm, one or two weeks after their hemorrhage. This is a major cause of stroke and death following SAH. A special type of CT scan, called CT perfusion, analyzes regional blood flow in the brain. We hypothesize that CT perfusion scans performed on admission and day 6 post-hemorrhage will enable us to predict which patients will go on to develop vasospasm.
Eligibility Criteria
This trial is for individuals aged 18-75 who have had a brain hemorrhage due to a ruptured aneurysm and can consent to participate. They must be able to attend follow-up visits and not be in another study, pregnant, breastfeeding, or expected to pass away within 24 hours.Inclusion Criteria
Patient or next of kin or person with appropriate power of attorney has provided written informed consent
Patient is willing and available for study follow-up visits
Patient has not been previously entered into this study
+2 more
Exclusion Criteria
Inability to obtain informed written consent
Patient history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)
Patient is currently breast feeding, or pregnant
+3 more
Participant Groups
The trial tests if CT perfusion scans can predict vasospasm—a dangerous narrowing of blood vessels in the brain after hemorrhage—by performing scans when patients are admitted and again on day six.
1Treatment groups
Experimental Treatment
Group I: CT PerfusionExperimental Treatment1 Intervention
All patients enrolled in the study
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Halifax Infirmary, Capital District Health AuthorityHalifax, Canada
Loading ...
Who Is Running the Clinical Trial?
Nova Scotia Health AuthorityLead Sponsor
Gwynedd PickettLead Sponsor